

Secukinumab Open Label Roll-over Extension Protocol

Last Update: Mar 30, 2025

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
ClinicalTrials.gov Identifier:

[NCT04638647](#)

Novartis Reference Number:CAIN457A02001B

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.

Condition

Autoimmunity, Inflammation

Phase

Phase4

Overall Status

Recruiting

Number of Participants

715

Start Date

Dec 22, 2020

Completion Date

Apr 04, 2030

Gender

All

Age(s)

6 Years - 100 Years (Child, Adult, Older Adult)

Interventions

Biological

Secukinumab s.c. injection

Secukinumab pre-filled syringes (PFS) for s.c. injection

Eligibility Criteria

Inclusion Criteria:

1. Signed informed consent must be obtained for adult participants before any assessment is performed. Written informed assent and parental permission (age as per local law) must be obtained for pediatric participants before any assessment is performed. If participants reach age of consent (age as per local law) during the study, they will need to also sign the corresponding study informed consent(s).
2. Ability to communicate effectively with the investigator, to understand and willing to comply with the requirements of the study.
3. Participant has completed treatment per protocol in a Novartis study of secukinumab (unless otherwise specified in a parent study protocol). Participants, who derive benefit from the treatment with secukinumab but have not completed the treatment in certain parent studies, due to parent study termination by Novartis, may be eligible if the termination was due to reasons other than safety or lack of efficacy (technical / administrative reasons).
4. Participant is deriving benefit from secukinumab, investigator believes he/she would continue to derive benefit from secukinumab and the benefit outweighs the risk, based on the investigator's judgement.
5. Participant is unable to obtain access to the marketed secukinumab formulation per local prescription and/or reimbursement guidelines.

Exclusion Criteria:

1. Participant has prematurely discontinued study treatment in the parent protocol.
2. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., in European Union (EU) 20 weeks).

Brazil

Novartis Investigative Site

Recruiting

Sao Jose do Rio Preto,15090 000,Brazil

Novartis Investigative Site

Recruiting

Salvador,BA,40150 150,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055 450,Brazil

Novartis Investigative Site

Recruiting

Juiz de Fora, MG, 36010-570, Brazil

Novartis Investigative Site

Recruiting

Sao Paulo, SP, 01244-030, Brazil

Novartis Investigative Site

Recruiting

Sao Paulo, SP, 04266-010, Brazil

Novartis Investigative Site

Recruiting

Rio de Janeiro, 20241-180, Brazil

Bulgaria

Novartis Investigative Site

Recruiting

Sofia, 1407, Bulgaria

Novartis Investigative Site

Recruiting

Plovdiv, 4002, Bulgaria

Novartis Investigative Site

Recruiting

Sofia, 1431, Bulgaria

Novartis Investigative Site

Recruiting

Sofia, 1784, Bulgaria

Novartis Investigative Site

Recruiting

Pleven, 5800, Bulgaria

China

Novartis Investigative Site

Novartis Investigative Site

Recruiting

Zhejiang,315016,China

Novartis Investigative Site

Recruiting

Beijing,100050,China

Novartis Investigative Site

Recruiting

Changsha,Hunan,410011,China

Novartis Investigative Site

Recruiting

Beijing,100000,China

Novartis Investigative Site

Recruiting

Xiamen,Fujian,361001,China

Novartis Investigative Site

Recruiting

Chang Chun,Jilin,130021,China

Novartis Investigative Site

Recruiting

Baotou,Inner Mongolia,014010,China

Novartis Investigative Site

Recruiting

Jinan,250012,China

Novartis Investigative Site

Recruiting

Guang Zhou,Guangdong,510120,China

Novartis Investigative Site

Recruiting

Beijing,100730,China

Novartis Investigative Site

Recruiting

Linyi,Shandong,276000,China

Novartis Investigative Site

Recruiting

Hohhot,Inner Mongolia,10050,China

Novartis Investigative Site

Recruiting

Shanghai,200040,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510080,China

Novartis Investigative Site

Recruiting

Chengdu,Sichuan,610041,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210009,China

Novartis Investigative Site

Recruiting

Shanghai,200050,China

Novartis Investigative Site

Recruiting

Shantou,Guangdong,515041,China

Novartis Investigative Site

Recruiting

Urumqi,Xinjiang,830001,China

Novartis Investigative Site

Recruiting

Hefei,Anhui,230601,China

Novartis Investigative Site

Recruiting

Yangzhou,Jiangsu,225001,China

Novartis Investigative Site

Recruiting

Shanghai,200127,China

Novartis Investigative Site

Recruiting

Shenzhen,Guangdong,518020,China

Novartis Investigative Site

Recruiting

KunMing,Yun Nan,650000,China

Novartis Investigative Site

Recruiting

Beijing,Beijing,100044,China

Novartis Investigative Site

Recruiting

Nanchang,Jiangxi,330006,China

Novartis Investigative Site

Recruiting

Tianjin,300052,China

Novartis Investigative Site

Recruiting

Wuhan,Hubei,430030,China

Novartis Investigative Site

Recruiting

Wenzhou,Zhejiang,325000,China

Novartis Investigative Site

Recruiting

Chongqing,Chongqing,400010,China

Novartis Investigative Site

Recruiting

Pingxiang,Jiangxi,337000,China

Colombia

Novartis Investigative Site

Recruiting

Bucaramanga,Santander,0001,Colombia

Novartis Investigative Site

Recruiting

Ibague,Tolima,730006,Colombia

Czechia

Novartis Investigative Site

Recruiting

Praha 11,14900,Czechia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Novartis Investigative Site

Recruiting

Praha 4,140 59,Czechia

Novartis Investigative Site

Recruiting

Ostrava,Czech Republic,772 00,Czechia

Novartis Investigative Site

Recruiting

Praha 5,150 06,Czechia

Novartis Investigative Site

Recruiting

Brno-Zidonice,CZE,61500,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

Novartis Investigative Site

Recruiting

Hradec Kralove,CZE,500 05,Czechia

Novartis Investigative Site

Recruiting

Brno Bohunice,625 00,Czechia

Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01009,Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01010,Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01001,Guatemala

India

Novartis Investigative Site

Recruiting

Nashik,Maharashtra,422101,India

Italy

Novartis Investigative Site

Recruiting

Firenze,FI,50134,Italy

Poland

Novartis Investigative Site

Recruiting

Bialystok,15-351,Poland

Novartis Investigative Site

Recruiting

Warszawa,02 637,Poland

Novartis Investigative Site

Recruiting

Sochaczew,96-500,Poland

Novartis Investigative Site

Recruiting

Torun,87-100,Poland

Portugal

Novartis Investigative Site

Recruiting

Lisboa,1649 035,Portugal

Russian Federation

Novartis Investigative Site

Recruiting

Yaroslavl,150003,Russian Federation

Novartis Investigative Site

Recruiting

Saint Petersburg,197198,Russian Federation

South Africa

Novartis Investigative Site

Recruiting

Panorama,Western Cape,7500,South Africa

Novartis Investigative Site

Recruiting

Stellenbosch,7600,South Africa

Spain

Novartis Investigative Site

Recruiting

Santiago De Compostela,Galicia,15706,Spain

Novartis Investigative Site

Recruiting

Madrid,28046,Spain

Novartis Investigative Site

Recruiting

Madrid,28009,Spain

Novartis Investigative Site

Recruiting

Valencia,46026,Spain

Switzerland

Novartis Investigative Site

Recruiting

Bern,3010,Switzerland

Novartis Investigative Site

Recruiting

St Gallen,9007,Switzerland

United States

Accurate Clinical Research Inc

Recruiting

San Antonio,Texas,78229,United States

Viet Ta

Email: vta@accurateclinicalresearch.com

Philip Waller

Oregon Health Sciences University

Recruiting

Portland,Oregon,97239,United States

Atul Deodhar

Yuki Harry

Phone: [503-494-5742](tel:503-494-5742)

Email: harryy@ohsu.edu

FL Medical Clinic Orlando Health

Recruiting

Zephyrhills,Florida,33542,United States

Bonnie Pacheco

Phone: [813-782-1234](tel:813-782-1234)

Email: nursebonnie81@gmail.com

Natalie Faith

West Tennessee Research Institute

Recruiting

Jackson, Tennessee, 38305, United States

Jacob A. Aelion

Kim Smith

Phone: [731-664-7824](tel:731-664-7824)

Email: ksmith@arthritisclinic.org

Willow Rheumatology Wellness

Recruiting

Willowbrook, Illinois, 60527, United States

Angela R Crowley

Swarnika Sampat

Email: swarnnie@gmail.com

Altoona Center for Clin Res

Recruiting

Duncansville, Pennsylvania, 16635, United States

Alan J Kivitz

Mary Beyer

Phone: [814-693-0300](tel:814-693-0300)

Email: marybeyer@altoonaresearch.com

Rheumatology Associates of South Florida

Recruiting

Boca Raton, Florida, 33486, United States

Michelle Jacobs

Phone: [561-361-6547](tel:561-361-6547)

Email: rasfresearch@gmail.com

Shawn Baca

Rheumatology Pulmonary Clinic

Recruiting

Beckley, West Virginia, 25801, United States

Catie Webb

Phone: [304-256-0242](tel:304-256-0242)

Email: webb.catie421@gmail.com

Wassim S Saikali

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://uat2.novartis.com/clinicaltrials/study/nct04638647>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT04638647>
2. [#trial-eligibility](#)
3. <mailto:vta@accurateclinicalresearch.com>
4. <tel:503-494-5742>
5. <mailto:harryy@ohsu.edu>
6. <tel:813-782-1234>
7. <mailto:nursebonnie81@gmail.com>
8. <tel:731-664-7824>
9. <mailto:ksmith@arthritisclinic.org>
10. <mailto:swarnnie@gmail.com>
11. <tel:814-693-0300>
12. <mailto:marybeyer@altonaresearch.com>
13. <tel:561-361-6547>
14. <mailto:rasfresearch@gmail.com>
15. <tel:304-256-0242>
16. <mailto:webb.catie421@gmail.com>
17. <tel:+41613241111>
18. <mailto:>
19. <tel:1-888-669-6682>
20. <mailto:novartis.email@novartis.com>